Introduction {#Sec1}
============

*Staphylococcus aureus* (*S. aureus*) is a leading cause of nosocomial and community-acquired infections in every region of world. The increasing prevalence of methicillin resistance among *Staphylococci* is an increasing problem (Yilmaz et al. [@CR28]). This has led to the renewed interest in the usage of macrolide--lincosamide--streptogramin B (MLS~B~) antibiotics to treat *S. aureus* infections with clindamycin being the preferred agent due to its excellent pharmacokinetic properties (Deotale et al. [@CR7]). However, the wide spread use of MLS~B~ antibiotics has led to an increase in the number of *Staphylococcal* strains acquiring resistance to MLS~B~ antibiotics (Ajantha et al. [@CR1]).

Resistance to MLS~B~ can occur by two different mechanisms: an active efflux mechanism encoded by the *msrA* gene (macrolides Streptogramin B resistance) and ribosomal target modification encoded by the *erm* gene (MLS~B~ resistance) (Leclercq [@CR16]). The expression of the MLS~B~ phenotype can be constitutive or inducible in the presence of low levels of inducers, such as erythromycin. *erm* genes encode enzymes that confer inducible or constitutive resistance to MLS agents via methylation of the 23S ribosomal RNA, thereby reducing binding by MLS agents to the ribosome (Fiebelkorn et al. [@CR9]). In vitro, *S. aureus* isolates with constitutive resistance are resistant to erythromycin and clindamycin, and isolates with inducible resistance are resistant to erythromycin, but appear susceptible to clindamycin. In vivo, therapy with clindamycin may select for constitutive *erm* mutants (Leclercq [@CR16]) that may lead to clinical failure (Siberry et al. [@CR26]).

iMLS~B~ (inducible clindamycin) is not recognized using standard susceptibility test methods, including standard broth-based or agar dilution susceptibility tests (Fiebelkorn et al. [@CR9]), including the Vitek system (Schreckenberger et al. [@CR24]) and disc diffusion testing with erythromycin (E) and clindamycin (CL) discs (double discs) in nonadjacent positions (Gadepalli et al. [@CR11]). Further reports on inducible clindamycin resistance are scanty in India. Therefore the present study was undertaken to determine the incidence of MLS~B~ resistance in the clinical isolates of *S. aureus* and to study the antibiotic sensitivity pattern of *S. aureus* isolates having the iMLS~B~ phenotype.

Materials and methods {#Sec2}
=====================

This prospective study was conducted for a period of 7 months from July 2010 to January 2011. A total of 153 *Staphylococcal* isolates were recovered from various clinical samples at the Microbiology Laboratory of Sri Bhagawan Mahaveer Jain hospital, a tertiary care hospital in Bangalore. Duplicate isolates from the same patient were not included in the study. Of 153 *S. aureus* isolates, 110 (71.89 %) were recovered from pus, 13 (8.49 %) from sputum, 11 (7.18 %) from ear swab, 9 (5.88 %) from blood, 5 (3.26 %) from urine and 5 (3.26 %) from tissue bits.

Isolates were identified up to species level by conventional methods (Gram stain, growth on mannitol salt agar, slide and tube coagulase test, DNase test and by biochemical test) (Kloos and Banerman [@CR15]).

Antibiotic susceptibility testing {#Sec3}
---------------------------------

The isolates were subjected to susceptibility testing by Kirby Bauer disc diffusion method on Mueller--Hinton agar plates using erythromycin (15 μg), clindamycin (2 μg), mupirocin (5 μg), fusidic acid (30 μg), pristinomycin (15 μg), linezolid (30 μg), vancomycin (30 μg), teicoplanin (30 μg), rifampicin (5 μg), chloramphenicol (30 μg), co-trimoxazole (30 μg), ciprofloxacin (5 μg), gentamicin (30 μg), amikacin (30 μg), and tetracycline (30 μg). The results were interpreted as per Clinical Laboratory Standards Institute (CLSI) guidelines (Clinical and Laboratory Standards Institute [@CR5]) methicillin resistance was detected by cefoxitin disc diffusion method and by oxacillin screen agar (5 % NaCl, 6 μg/ml oxacillin).

D-Test {#Sec4}
------

Isolates that were erythromycin resistant was tested for inducible resistance by the 'D test' as per CLSI guidelines. Erythromycin (15 μg) disc was placed at a distance of 15 mm (edge to edge) from clindamycin (2 μg) on Mueller--Hinton agar plates previously inoculated with 0.5 McFarland bacterial suspensions. Plates were analyzed after 18 h of incubation at 37 °C. Interpretation of the inhibition zone diameters was as follows: If an isolate was erythromycin resistant and clindamycin susceptible, with a D-shaped inhibition zone around the clindamycin disc, it was considered to be positive for inducible resistance (D test positive, iMLS~B~ phenotype). If the isolate was erythromycin resistant and clindamycin susceptible, with both zones of inhibition showing a circular shape, the isolate was considered to be negative for inducible resistance (D test negative, MS phenotype), but to have an active efflux pump. If the isolate was erythromycin resistant and clindamycin resistant, the isolate was considered to have the macrolide--lincosamide--Streptogramin B constitutive (cMLS~B~ phenotype) (Steward et al. [@CR27]). The quality control of the erythromycin and clindamycin disc was performed with *S. aureus* ATCC 25923.

Statistical analysis {#Sec5}
--------------------

Demographic data were collected and SPSS version 18 was used for all statistical analysis. Odds ratios (OR) and 95 % confidence intervals (95 % CI) were calculated. *P* \< 0.05 was considered statistically significant.

Results {#Sec6}
=======

Of the 153 *S. aureus* isolates, 42 (27.45 %) were resistant to methicillin-resistant *S. aureus* (MRSA) and 111 (72.54 %) were methicillin-susceptible *S. aureus* (MSSA). Of the total 153 *S. aureus* isolates, 144 isolates (94.11 %) were coagulase positive and 9 (5.88 %) were coagulase negative. A total of 38 of the coagulase-positive *S. aureus* isolates showed methicillin resistant and four coagulase-negative isolates showed methicillin resistance.

Of the total 42 MRSA, 32 (76.19 %) isolates belonged to male and 10 (23.80 %) to female patients. Our study showed the highest percentage of MRSA occurrence in patients with the age group of 20--30 years. The number of MRSA isolates was significantly different among various age groups (*P* \< 0.0001).

Out of the 153 *S. aureus* isolates, 63 (41.17 %) of them were erythromycin resistant. These isolates when subjected to D test, 20 (13.07 %) isolates showed resistant to erythromycin and clindamycin indicating constitutive MLS~B~ phenotype. Out of the 43 isolates that showed clindamycin sensitivity, 14 (9.15 %) isolates showed positive D test indicating inducible MLS~B~ phenotype, while 29 (18.95 %) showed true sensitivity to clindamycin (D test negative indicating MS phenotype). 58.82 % had the susceptible phenotype (E-S, CL-S) (Table [1](#Tab1){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}).Table 1Susceptibility to erythromycin and clindamycin among all *Staphylococcal* isolatesPhenotypesMRSA (%)MSSA (%)Total (%)E-S, CL-S26 (16.99)64 (41.83)90 (58.82)E-R, CL-R (constitutive MLS~B~)8 (5.22)12 (7.84)20 (13.07)E-R, CL-S, D test positive (inducible MLS~B~)1 (0.65)13 (8.49)14 (9.15)E-R, CL-S, D test negative (MS)9 (5.88)20 (13.07)29 (18.95)Total42 (28.74)111 (71.23)153*E* erythromycin, *CL* clindamycin, *S* sensitive, *R* resistant, *constitutive MLS*~*B*~ constitutive resistance to clindamycin, *inducible MLS*~*B*~ inducible resistance to clindamycin, *MS* ms phenotypeFig. 1Disc diffusion test for inducible clindamycin resistance. **a** Circular zone of inhibition around clindamycin suggestive of MS phenotype. **b** D-shaped zone of inhibition around clindamycin suggestive of inducible MLS~B~ phenotype

Constitutive MLS~B~ phenotype was 5.22 % and the inducible MLS~B~ phenotype was 0.65 % in MRSA, while in methicillin sensitive *Staphylococcal* isolates, the constitutive MLS~B~ phenotype was 7.84 % and the inducible MLS~B~ phenotype was 8.49 %.

The E-S and CL-S phenotype predominated over the inducible resistance phenotype and constitutive resistance phenotype among MRSA and MSSA isolates. The percentage of inducible and constitutive resistance was higher amongst MSSA isolates when compared with MRSA isolates. Out of the 14 iMLS~B~ phenotype *S. aureus* isolates, 11 (78.57 %) isolates were isolated from pus, followed by 2 (14.28 %) isolates that were isolated from ear swab and 1 (7.14 %) isolate from tissue bits. iMLS~B~ phenotype was found more in males (71.42 %).

When the results were statistically compared between methicillin-sensitive *Staphylococcal* isolates, the constitutive CL-R phenotype was determined to be 1.5 times greater (*P* = 0.002, OR 14.38, 95 % CI 5.33--21.49) and the inducible resistance phenotype 13 times greater (*P* = 0.0002, OR 18.30, 95 % CI 8.72--25.77) than that in methicillin-resistant *Staphylococcal* isolates.

The susceptibility of iMLS~B~ phenotypes isolated were amikacin 85.71 %, gentamicin 78.57 %, ciprofloxacin 50 %, cotrimoxazole 57.14 % and tetracycline 85.71 %. iMLS~B~ phenotype *S. aureus* isolates were 100 % sensitive to vancomycin, teicoplanin, mupirocin, fusidic acid and linezolid, respectively.

Discussion {#Sec7}
==========

The increasing frequency of *Staphylococcal* infections among patients and changing patterns in antimicrobial resistance have led to renewed interest in the use of clindamycin therapy to treat such infections (Frank et al. [@CR10]). Clindamycin is frequently used to treat skin and bone infections because of its tolerability, cost, oral form and excellent tissue penetration, and the fact that it accumulates in abscesses and no renal dosing adjustments are needed (Kasten [@CR14]). Good oral absorption makes it an important option in outpatient therapy or as follow-up after intravenous therapy. Clindamycin is a good alternative for the treatment of both methicillin-resistant and susceptible *Staphylococcal* infections (Fiebelkorn et al. [@CR9]).

The very high rates of methicillin resistance among *S. aureus* isolates have been noted in developed countries; especially, in Western Pacific regions both in community-acquired and nosocomial infections (Diekema et al. [@CR8]). In West Asia, MRSA prevalence ranged from 12 to 49.4 % in six different hospitals of Saudi Arabia (Hussain et al. [@CR13]; Baddour et al. [@CR2]). In European countries, MRSA rates varied from 0.6 % in Sweden to 40.2--45 % in Belgium, Greece, Ireland, Italy, UK, and Israel (Blandino et al. [@CR3]; Sader et al. [@CR23]). In a study performed in 17 different regions of Russia, methicillin resistance among *S. aureus* strains was between 0 and 89.5 %. In our study, methicillin resistance *S. aureus* was found to be 27.45 %. Similar prevalence rate of MRSA was obtained from other workers in India---22.8 % by Pal and Ayyagari ([@CR20]), 26.9 % by Shittu and Lin ([@CR25]) and 26.6 % Mehta et al. ([@CR18]). Although lesser and higher percentage was obtained by other workers---2.4 % Pulimood et al. ([@CR21]), 54.85 by Dar et al. ([@CR6]) and 65 % by Borg et al. ([@CR4]). The differences in the prevalence of MRSA among different countries and between different regions in a country could be due to difference in the study design, population and geographical distribution and the variation is probably due to differential clonal expansion and drug pressure in community. Further, it emphasizes the importance of local surveillance in generating relevant local resistance data that can guide empiric therapy.

In our study, there was no isolate with reduced susceptibility to glycopeptides, and all isolates were found susceptible to vancomycin, teicoplanin, fusidic acid, mupirocin and linezolid. Rahbar and Hajia ([@CR22]) also found all iMLS~B~ isolates susceptible to linezolid and vancomycin. Disc diffusion test for vancomycin in *Staphylococci* is no longer recommended by CLSI starting from 2009 and that the ability of teicoplanin disc diffusion test to differentiate resistant from susceptible strains is not known (Clinical and Laboratory Standards Institute [@CR5]).

The incidence of MLS~B~ resistance varies significantly by geographical region. In our study, the percentage of inducible resistance and MS phenotype was higher amongst MSSA (8.49 and 13.07 %) when compared with MRSA (0.65 and 5.88 %). This was in concordance with a few of the studies reported before. Schreckenberger et al. ([@CR24]) and Levin et al. ([@CR17]) showed higher percentage of inducible resitance in MSSA (19--20 %) as compared to MRSA (7--12 %), 12.5 % MRSA and 68 % MSSA, respectively. The true incidence of the MLS~B~ phenotype of *S. aureus* depends on the patient population studied, and the geographical region, the hospital characteristics and methicillin susceptibility (MRSA or MSSA).

In our study, 8.49 % MSSA isolates were of the iMLS~B~ phenotype, which is in concordance with other workers, who have found that 4--15 % of their MSSA isolates were of the iMLS~B~ phenotype (Yilmaz et al. [@CR28]). O'Sullivan et al. ([@CR19]) reported that a 15-mm distance, in an edge to edge position, had a 100 % sensitivity and specificity, while the 22-mm distance, in an edge to edge position, had a sensitivity of 87 % and a specificity of 100 % when compared with the presence of the *erm* gene as the gold standard for the detection of inducible CL resistance. Further Ajantha et al. ([@CR1]) in their study identified additional 14 % iMLS~B~ strains with 15 mm edge to edge interdisc distance. In the present study, we have maintained the narrow disc range to reduce the error rate of identifying iMLS~B~ isolates.

In the present study, 13.07 % of erythromycin-resistant *Staphylococcal* isolates showed true clindamycin susceptibility. Patients with infections caused by such isolates can be treated with clindamycin without emergence of resistance during therapy. In the current study, iMLS~B~ phenotype was found more in males (71.42 %). Male patient predominance most likely due to the fact that exposure is greater.

In the light of the restricted range of antibiotics available for the treatment of methicillin-resistant *Staphylococcal* infections and the known limitations of vancomycin, clindamycin should be considered for the management of serious soft tissue infections. Further, using clindamycin use of vancomycin can be avoided (Gupta et al. [@CR12]). In addition, such testing can provide information about resistant to MLS phenotype group of antibiotics and can be useful for surveillance studies related to MLS resistance in *Staphylococci*.

We gratefully acknowledge Mrs. Geetha Bhat, Consultant Microbiologist, Sri Bhagawan Mahaveer Jain hospital for providing clinical specimens.

Conflict of interest {#d30e810}
====================

None.
